[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-acute-respiratory-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-acute-respiratory-infection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100614415","effectiveness-of-immunization-in-preventing-severe-acute-respiratory-infection-rsv-100614415",false,"NCT07279298","Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV","Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection Associated With Respiratory Syncytial Virus-RSV- in Infants Under 6 Months of Age in Bogotá: a Case-control Study With a Negative Test Design","Inclusion Criteria:\n\n* Age: Infants younger than 6 months at the time of hospital admission.\n* Residence: Maternal residence in Bogotá, Colombia, verified through clinical record, identification document, or health system registry.\n* Clinical Condition: Hospitalization due to severe acute respiratory infection (SARI) meeting the district operational definition (presence of fever, cough, and\u002For signs of respiratory distress, requiring inpatient management).\n* Laboratory Testing: Respiratory specimen collected and tested for RSV by RT-PCR or validated antigen test within ≤48 hours of hospital admission, or repeated within 24-48 hours if initial test is negative.\n* Exposure Eligibility Window: Infant born ≥5 weeks after the start of the RSVpreF maternal vaccination campaign in Bogotá, ensuring opportunity for maternal immunization.\n\nExclusion Criteria:\n\n* Prematurity: Infants born at ≤32 weeks of gestation.\n* Healthcare-associated respiratory infection: Symptom onset \\>48 hours after hospital admission for another condition.\n* Non-respiratory hospital admission: Primary reason for hospitalization unrelated to respiratory disease (e.g., trauma, elective surgery).\n* Vaccination status unverifiable: Inability to confirm maternal RSVpreF vaccination status after reasonable attempts to verify through registry, vaccination card, or prenatal documentation.\n* Duplicate episodes: Readmission for the same respiratory episode ≤14 days after discharge (only the first episode will be included).\n* Delayed sampling: First respiratory sample obtained \\>48-72 hours after initial admission to the health system.\n* Lethal congenital conditions: Congenital or genetic disorders incompatible with life or that substantially alter the expected clinical course.\n* Concurrent interventional study participation: Enrollment in another clinical trial that may affect respiratory outcomes.\n* Inability to establish mother-infant linkage due to adoption, loss of parental custody, or absence of biological maternal records.","ALL","1 Day","180 Days",{"count":20,"type":21},1097,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the real-world effectiveness of two preventive immunization strategies against Respiratory Syncytial Virus (RSV)-associated severe acute respiratory infection in infants less than six months of age in Bogotá, Colombia. The strategies include maternal vaccination with RSVpreF administered between 28 and 36 weeks of gestation and neonatal immunization with nirsevimab for infants born to mothers who did not receive RSVpreF during pregnancy. Using a test-negative case-control design embedded in the city's sentinel surveillance system, infants hospitalized for severe respiratory infection will be systematically tested for RSV. Comparative vaccine effectiveness will be estimated to determine the impact of maternal RSV vaccination and neonatal monoclonal antibody immunization on RSV-associated hospitalizations, intensive care admissions, and mortality. The study will generate real-world evidence to inform local and regional public health decisions and guide the implementation of cost-effective hybrid immunization strategies against RSV in middle-income settings.",[25,26,27,28],"Respiratory Syncytial Virus Infections","Severe Acute Respiratory Infection","Bronchiolitis, Viral","Viral Respiratory Tract Infection","NOT_YET_RECRUITING","2025-12-01",{"date":32,"type":33},"2025-12-12","ACTUAL",{"date":35,"type":21},"2026-02-01",{"date":37,"type":21},"2027-07-31",{"name":39,"class":40},"Bogotá District Health Secretariat","OTHER_GOV",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100247363","short-period-incidence-study-of-severe-acute-respiratory-illness-100247363","NCT02498587","Short Period Incidence Study of Severe Acute Respiratory Illness","SPRINT-SARI","Inclusion Criteria:\n\n* A history of feverishness or measured fever of ≥ 38 deg C;\n* Cough;\n* Dyspnoea (shortness of breath) OR Tachypnoea.\n\nExclusion Criteria:\n\n• No exclusion criteria",{"count":49,"type":21},15000,"This is a multi-centre, prospective, short period incidence observational study of patients in participating hospitals and intensive care units (ICUs) with SARI. The study period will occur, in both Northern and Southern hemispheric winters. The study period will comprise a 5 to 7-day cohort study in which patients meeting a SARI case-definition, who are newly admitted to the hospitals \u002F ICUs at participating sites, will be included in the study. The study will be conducted in 20 to 40-hospital\u002F ICU-based research networks globally. All clinical information and sample data will only be recorded if taken as part of the routine clinical practice at each site and only fully anonymised and de-identified data will be submitted centrally.\n\nThe primary aim of this study is to establishing a research response capability for a future epidemic \u002F pandemic through a global SARI observational study. The secondary aim of this study is to investigate the descriptive epidemiology and microbiology profiles of patients with SARI. The tertiary aim of this study is to assess the Ethics, Administrative, Regulatory and Logistic (EARL) barriers to conducting pandemic research on a global level.",[26],[26],"RECRUITING","2024-08-07",{"date":56,"type":33},"2024-08-09",{"date":58,"type":33},"2016-01",{"date":60,"type":21},"2026-12",{"name":62,"class":63},"Australian and New Zealand Intensive Care Research Centre","OTHER",1]